Compare Illumina, Inc. (ILMN) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Annaly Capital Management, Inc. — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Annaly Capital Management, Inc. trades at $22.87 (market cap $16.63B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NLY | |
|---|---|---|
Market Cap | $27.94B | $16.63B |
Sector | Health | Financials |
52-Week High | $194.33 | $24.40 |
52-Week Low | $91.00 | $19.96 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Annaly Capital Management (NLY) trades at $22.65, down 1.56% today, with a bullish technical signal and consistent earnings beats. The stock offers a high dividend yield of 13% and trades below the consensus price target of $24.80. Recent Q2 2026 results highlight strong net interest income growth, though mortgage market volatility remains a concern.
Outlook is positive with analyst support (57% buy ratings), but risks include interest rate sensitivity and leverage. The stock presents income opportunity with upside potential, but investors should weigh dividend sustainability against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
